Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 3/20 | 0.53 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.53 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514303 | 1.00 | NQO2 (0.53) | NQO2MTNR1AMTNR1BABCB1KDM4E | |
| SCHEMBL8514302 | 1.00 | NQO2 (0.53) | NQO2MTNR1AMTNR1BABCB1KDM4E | |
| SCHEMBL1470548 | 0.92 | NQO2 (0.61) | NQO2MTNR1AMTNR1BKDM4ECYP19A1 | |
| SCHEMBL1470545 | 0.92 | NQO2 (0.61) | NQO2MTNR1AMTNR1BKDM4ECYP19A1 | |
| SCHEMBL12749769 | 0.92 | NQO2 (0.61) | NQO2MTNR1AMTNR1BKDM4ECYP19A1 | |
| SCHEMBL3004692 | 0.90 | CYP19A1 (0.51) | NQO2MTNR1AMTNR1BKDM4EMAPT | |
| SCHEMBL2432831 | 0.90 | CYP19A1 (0.51) | NQO2MTNR1AMTNR1BKDM4EMAPT | |
| SCHEMBL12550714 | 0.86 | RXRA (0.53) | NQO2MTNR1AMTNR1BKDM4EMAPT | |
| SCHEMBL3894416 | 0.83 | NQO2 (0.49) | NQO2MTNR1AMTNR1BABCB1KDM4E | |
| SCHEMBL3894420 | 0.83 | NQO2 (0.49) | NQO2MTNR1AMTNR1BABCB1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016046833-A2 | IMPROVED PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-03-31 | — | — | WO | disclosed |
| US-8779199-B2 | Agomelatine intermediates and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| WO-2014064706-A1 | PROCESSES FOR THE PREPARATION OF AGOMELATINE USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2014-05-01 | — | — | WO | disclosed |
| EP-2703383-A1 | Process for the preparation of agomelatine | Procos S.p.A. (IT) | 2014-03-05 | — | — | EP | disclosed |
| US-8653281-B2 | Process for the manufacture of agomelatine and its intermediate | NHWA PHARMA. CORPORATION (CN) | 2014-02-18 | — | — | US | disclosed |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATORIES SERVIER (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012070025-A1 | PROCESS FOR THE PREPARATION OF AGOMELATINE | CADILA PHARMACEUTICALS LTD (IN) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | COMT, AGO2, MC5R | NQO2 3451/4885MTNR1A 9/4885MTNR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.